PLRX

SEC source: 0001209191-23-035520 · doc4.xml · derivative · entry 1

CROWELL GAYLE A · CIK 0001250893 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 14,000 shares

Expires 2033-06-07

F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 7th, 2023 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 7th, 2023 grant date, or (ii) the 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

SEC source: 0001209191-23-035501 · doc4.xml · derivative · entry 1

Bruhn Suzanne Louise · CIK 0001517790 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 14,000 shares

Expires 2033-06-07

F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 7th, 2023 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 7th, 2023 grant date, or (ii) the 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

SEC source: 0001209191-23-035529 · doc4.xml · derivative · entry 1

Curnutte John T · CIK 0001574589 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 14,000 shares

Expires 2033-06-07

F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 7th, 2023 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 7th, 2023 grant date, or (ii) the 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

SEC source: 0001209191-23-035511 · doc4.xml · derivative · entry 1

Cline Darren S · CIK 0001633639 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 14,000 shares

Expires 2033-06-07

F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 7th, 2023 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 7th, 2023 grant date, or (ii) the 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

SEC source: 0001209191-23-035533 · doc4.xml · derivative · entry 1

Knobil Katharine · CIK 0001768011 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 14,000 shares

Expires 2033-06-07

F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 7th, 2023 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 7th, 2023 grant date, or (ii) the 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

SEC source: 0001209191-23-022376 · doc4.xml · nonDerivative · entry 3

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,789

F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2022.

F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.27 to $27.64, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4.

SEC source: 0001209191-23-022376 · doc4.xml · nonDerivative · entry 2

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,989

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 4, 2022.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.24 to $27.17, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.

SEC source: 0001209191-23-022364 · doc4.xml · nonDerivative · entry 1

Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 148,470

F1 · price: Represents a nondiscretionary sale by the plan established on behalf of the Reporting Person on July 28, 2022 in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $25.88 to $27.235, inclusive, on March 30, 2023 and March 31, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.

SEC source: 0001209191-23-022362 · doc4.xml · nonDerivative · entry 1

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 274,753

F1 · price: Represents a nondiscretionary sale by the plan established on behalf of the Reporting Person on July 28, 2022 in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $25.88 to $27.235, inclusive, on March 30, 2023 and March 31, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.

SEC source: 0001209191-23-022374 · doc4.xml · nonDerivative · entry 1

Lefebvre Eric · CIK 0001614741 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 145,786

F1 · price: Represents a nondiscretionary sale by the plan established on behalf of the Reporting Person on July 28, 2022 in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $25.88 to $27.235, inclusive, on March 30, 2023 and March 31, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.

SEC source: 0001209191-23-022369 · doc4.xml · nonDerivative · entry 1

Hull Hans · CIK 0001614876 · Chief Business Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 201,964

F1 · price: Represents a nondiscretionary sale by the plan established on behalf of the Reporting Person on July 28, 2022 in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $25.88 to $27.235, inclusive, on March 30, 2023 and March 31, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.

SEC source: 0001209191-23-022376 · doc4.xml · nonDerivative · entry 1

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,666

F1 · price: Represents a nondiscretionary sale by the plan established on behalf of the Reporting Person on July 28, 2022 in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $25.88 to $27.235, inclusive, on March 30, 2023 and March 31, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.

SEC source: 0001209191-23-021917 · doc4.xml · nonDerivative · entry 1

Cummings Keith Lamont · CIK 0001809204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,430

F1 · shares: On July 28, 2022, the Reporting Person was granted 77,500 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On March 29, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 19,375 shares.

F2 · balance_after: Includes 631 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program.

SEC source: 0001209191-23-021915 · doc4.xml · nonDerivative · entry 1

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 310,092

F1 · shares: On July 28, 2022, the Reporting Person was granted 275,000 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On March 29, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 68,749 shares.

F2 · balance_after: Includes 1,231 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program.

SEC source: 0001209191-23-021921 · doc4.xml · nonDerivative · entry 1

Lefebvre Eric · CIK 0001614741 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,031

F1 · shares: On July 28, 2022, the Reporting Person was granted 87,500 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On March 29, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 21,874 shares.

F2 · balance_after: Includes 1,231 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program.

SEC source: 0001209191-23-021919 · doc4.xml · nonDerivative · entry 1

Hull Hans · CIK 0001614876 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 211,000

F1 · shares: On July 28, 2022, the Reporting Person was granted 70,313 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On March 29,2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 17,578 shares.

F2 · balance_after: Includes 1,231 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program.

SEC source: 0001209191-23-021927 · doc4.xml · nonDerivative · entry 1

Ouimette Mike · CIK 0001822619 · General Counsel & Corp. Sec'y

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,540

F1 · shares: On July 28, 2022, the Reporting Person was granted 54,375 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On March 29, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 13,593 shares.

SEC source: 0001209191-23-017217 · doc4.xml · derivative · entry 1

MCCOURT Thomas A · CIK 0001478448 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2033-03-06

F1 · derivative.exercise_date: 1/36th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 6, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001209191-23-017213 · doc4.xml · derivative · entry 1

Cline Darren S · CIK 0001633639 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2033-03-06

F1 · derivative.exercise_date: 1/36th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 6, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001140361-23-004735 · form4.xml · derivative · entry 9

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 327,262

Underlying: Common Stock · 15,000 shares

Expires 2030-03-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 31, 2020 (or if there is no corresponding day in any such month, on the last day of such month), subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001140361-23-004735 · form4.xml · nonDerivative · entry 6

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,112

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022.

F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.84 to $34.56, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4.

SEC source: 0001140361-23-004735 · form4.xml · nonDerivative · entry 5

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,374

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022.

F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.84 to $33.83, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4.

SEC source: 0001140361-23-004735 · form4.xml · nonDerivative · entry 4

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 255,112

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-23-004735 · form4.xml · derivative · entry 8

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 342,262

Underlying: Common Stock · 15,000 shares

Expires 2030-03-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 31, 2020 (or if there is no corresponding day in any such month, on the last day of such month), subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001140361-23-004735 · form4.xml · nonDerivative · entry 3

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,112

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.69 to $35.48, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.

SEC source: 0001140361-23-004735 · form4.xml · nonDerivative · entry 2

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 241,717

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.65 to $34.60, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.

SEC source: 0001140361-23-004735 · form4.xml · nonDerivative · entry 1

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 255,112

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-23-003977 · form4.xml · derivative · entry 15

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 357,262

Underlying: Common Stock · 15,000 shares

Expires 2030-03-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 31, 2020 (or if there is no corresponding day in any such month, on the last day of such month), subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001140361-23-003977 · form4.xml · nonDerivative · entry 10

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,112

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022.

F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.55 to $35.65, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) to this Form 4.

SEC source: 0001140361-23-003977 · form4.xml · nonDerivative · entry 9

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,217

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022.

F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.52 to $35.42, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4.

SEC source: 0001140361-23-003977 · form4.xml · nonDerivative · entry 8

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,657

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022.

F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.52 to $34.50, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4.

SEC source: 0001140361-23-003977 · form4.xml · nonDerivative · entry 7

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 255,112

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-23-003977 · form4.xml · derivative · entry 14

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 372,262

Underlying: Common Stock · 4,461 shares

Expires 2030-03-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 31, 2020 (or if there is no corresponding day in any such month, on the last day of such month), subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001140361-23-003977 · form4.xml · derivative · entry 13

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,841

Underlying: Common Stock · 10,539 shares

Expires 2029-01-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: 1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001140361-23-003977 · form4.xml · nonDerivative · entry 6

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,112

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022.

SEC source: 0001140361-23-003977 · form4.xml · nonDerivative · entry 5

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 255,112

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-23-003977 · form4.xml · nonDerivative · entry 4

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,651

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-23-003977 · form4.xml · derivative · entry 12

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,380

Underlying: Common Stock · 15,000 shares

Expires 2029-01-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: 1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001140361-23-003977 · form4.xml · nonDerivative · entry 3

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,112

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.56 to $34.92, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.

SEC source: 0001140361-23-003977 · form4.xml · nonDerivative · entry 2

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 243,717

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.56 to $34.55, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.

SEC source: 0001140361-23-003977 · form4.xml · nonDerivative · entry 1

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 255,112

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-23-003177 · form4.xml · nonDerivative · entry 9

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 409,317

F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022.

F5 · ownership.nature: Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001140361-23-003177 · form4.xml · nonDerivative · entry 8

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 409,538

F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022.

F8 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.63 to $36.54, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (8) to this Form 4.

F5 · ownership.nature: Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001140361-23-003177 · form4.xml · nonDerivative · entry 7

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,112

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022.

F7 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.87 to $36.45, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) to this Form 4.

SEC source: 0001140361-23-003177 · form4.xml · nonDerivative · entry 6

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 246,414

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022.

F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.87 to $35.85, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) to this Form 4.

SEC source: 0001140361-23-003177 · form4.xml · nonDerivative · entry 5

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 255,112

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-23-003177 · form4.xml · derivative · entry 12

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,380

Underlying: Common Stock · 15,000 shares

Expires 2029-01-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: 1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001140361-23-003177 · form4.xml · derivative · entry 11

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,380

Underlying: Common Stock · 15,000 shares

Expires 2029-01-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: 1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date.

SEC source: 0001140361-23-003177 · form4.xml · nonDerivative · entry 4

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 419,317

F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022.

F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.43, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4.

F5 · ownership.nature: Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001140361-23-003177 · form4.xml · nonDerivative · entry 3

Coulie Bernard · CIK 0001808895 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,112

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022.